LEVEL 38, MELBOURNE, VICTORIA, C3
.4
ACQUIRES CHIMERIC ANTIGEN RECEPTOR (CAR) PLATFORM TECHNOLOGY FOR PRECISION-ENHANCED CELL PRODUCTS
Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy
CONTINUES SUCCESSFUL FIRST YEAR LAUNCH WITH NET SALES OF US$30.3M IN MARCH QUARTER
R&D DAY FEATURES SIGNIFICANT COMMERCIAL PROGRESS & PLATFORM INNOVATION
Files New Issue Announcements with the Australian Securities Exchange
Change of Director’s Interest Notice
To Host R&D Day on April 8, 2026
Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Correspondence
Submission Upload